RESEARCH ARTICLE

EFFECT OF SUPPLEMENTATION WITH GLUTAMINE AND HYDROXYMETHYLIBUTIRATE OVER THE CELLS INVOLVED IN WOUND HEALING.

Men C Alejandra Patricia Salas González¹, Sevilla González María de la Luz² and Fuchs Tarlovsky Vanessa³.
1. Hospital General de México/ Instituto Politécnico Nacional.
2. Instituto Politécnico Nacional, Escuela Superior de Medicina.
3. Hospital General de México.

Abstract

Introduction: The healing process demands energy-protein needs higher than the normal requirement. Nutritional support in bloody areas is essential since it restores the capacity of the immune response facilitating healing, promotes angiogenesis and cell proliferation. Objective: To evaluate the effect of glutamine and hydroxymethylbutyrate supplementation on the cells involved in the healing of bloody areas. Methodology: Clinical, experimental, longitudinal, prospective, comparative, randomized trial in patients with diagnosis of bloody areas. Divided into control group and treatment group which received supplementation with glutamine (14g) and hydroxymethylbutyrate (3g) during 15 days. Tissue samples were taken for histopathologic evaluation. Differences between groups (Student's t) and effect size (Cohen's d) were analyzed. Results: Significant differences were reported in fibroblasts and angiogenesis (p <0.005) with a large effect size (d> 0.8); lymphocytes and granulocytes without significant differences (p <0.005) but with medium effect size. No side effects were reported. Conclusions: The mixture of glutamine and Hydroxymethylbutyrate has a positive effect in the cells involved in the inflammatory and proliferative phase of healing.

Introduction:

Nutrition in the patient with Diagnosis of bloody areas is a relevant issue, to generate the homeostatic equilibrium of the patient. It should be noted that, during the healing process, the energetic-protein demands increase¹. This triggers a systemic inflammatory response that leads to an increase in metabolic demands; if there’s also procedures such as trauma, burns, infections, and even the constant fasting to which these patients are subjected by the surgical toilet the protein requirement increases twice more than normal²,³,⁴,⁵,⁶. This contribution of energy and extra protein is necessary for the elaboration of cells involved in the wound healing process; if adequate substrates are not provided, this requirement is usually used from body reserves increasing the risk of muscle wasting, which leads to malnutrition⁴, delays angiogenesis, decreases collagen synthesis, prolongs the inflammatory phase involving damage to healthy tissue, decreases lymphocyte proliferation and the mechanical resistance of the skin delaying wound healing, resulting in chronic wounds⁷, leading up to a failed graft or flap. Within this context, the intake of the hospitalized patient does not meet the recommended daily requirement¹,⁶,⁸,⁹ to achieve a positive effect on the...
immune system, specially on certain amino acids involved in wound healing. There is a 70% deficiency in the amino acids in hospitalized patients, so the nutritional support in these patients is essential since it restores the capacity of the immune response, specifically as glutamine and hydroxymethylbutirate (HMB) for the adequate immune function and cells proliferation.

Supplementation with glutamine (14g / d) and HMB (3g / d) has positive effects, attributing benefits in the healing of wounds, through the increase of collagen deposits, muscle mass, lymphocytes and hemoglobin, decreasing wound size and inflammation.

The mix of these substances have demonstrated positive effects on patients who undergo this supplementation, a positive association has been observed in critical patients, post-surgical, diabetic foot, pressure ulcers, in patients with cancer and HIV, attributing benefits in the wound healing, through increased collagen deposits and hydroxyproline blood levels; however, the effect on the cells involved in the wound healing process is unknown. Given that, the phases of healing are characterized by the proliferation of cells of the immune system, it is very important to evaluate their evolution and proliferation by histopathological analysis.

**Material and methods:-**
Clinical, experimental, longitudinal, prospective, comparative, randomized trial where patients older than 18 years, with diagnosis of bloody areas hospitalized in the Plastic and Reconstructive Surgery service during the period August 2016 - June 2018 with negative pressure system and those who signed the informed consent were included. Patients with previous supplementation, smokers, glycosylated hemoglobin > 12%, renal failure, topical collagen therapy, collagen vascular disease, autoimmune disease, radio or chemotherapy, allergy to any ingredient (glutamine or HMB), diagnosed with chronic diseases, pregnancy and lactation were excluded. Those patients who did not have adherence to the treatment, who underwent graft or flap skin procedure before completing the supplementation, voluntary discharges and patients who decided to withdraw their informed consent were eliminated.

Once the patient met the inclusion criteria, was invited to participate in the research protocol, explaining what it consists of, as well as the benefits of Glutamine and HMB supplementation.

The protocol consisted in three stages:
First stage: Before the supplementation, under local anesthesia and by a standardized Medical Resident of the Plastic and Reconstructive Surgery Service, a sample of the edge of the affected tissue was taken after asepsis or surgical toilet; this is a routine procedure in the Service, the sample was sent to the Pathology Service for analysis (procedure described later). Patients were randomly assigned to control or treatment group. Doctors and laboratory technicians, who worked with the participants in the study, as well as the participants themselves, were blinded to if the patients were assigned to treatment or control group. Second stage: If the patient was part of treatment group the supplement was delivered (box 1) explaining that it must be taken once a day during 15 days diluted in approximately 250 ml of water. Individualized dietary guidance was given in order to improve nutritional status of participants. In case of being part of control group the patients was under observation during a period of 15 days.
Third stage: At the end of the supplementation, a second sample of the affected tissue was taken, by the procedure described above; to be analyzed in the laboratory by an experienced Physician Resident of the Pathology service.

**Box 1. Nutritional composition of supplement per envelope and intake indications**

| Component (g) | Amount |
|---------------|--------|
| Calories (kcal) | 68 |
| Protein of which: | 17 |
| Amino acids of which: | 17 |
| B-Hydroxy-methylbutirate (g) | 3 |
| L-Glutamine (g) | 14 |

Donated by: Evolution Nutraceutical Company S.A. de C.V. Prolongación Paseo de los Laureles No. 458-307. Colonia Bosques de las Lomas, Ciudad de México. CP 05120

The samples were analyzed by Giemsa stain for morphological differentiation in order to obtain the total number of units per field: lymphocytes, macrophages, granulocytes, fibroblasts and angiogenesis. In addition, subjects were asked if they experienced any symptoms, such as stomachache, dizziness, nausea, vomiting, headache, loss of
appetite, general weakness among others. A Kolmogorov-Smirnov test was used to check normality for continuous variables. A t-Student test was used for parametric data and Mann-Whitney U test for non parametric data. The study was conducted under the established terms of the Mexican General Health Law, Title Five and the Regulations of the General Health Law on Health Research (RLGS), and NOM-012-SSA3-2012, which establish the criteria for the execution of research projects for human health. This study also counts with the approval of the Committee of Ethics in Research and the Research Committee of the General Hospital of Mexico “Dr. Eduardo Liceaga”.

**Results:**
A total of 21 patients were invited; 4 were excluded because the treatment was not properly concluded, leaving 17 patients, of whom 9 were assigned to the control group (53%) and 8 to the treatment group (47%). The mean age of the total sample was 38.65 ± 14.47 years (Table 1).

| Variable          | Beginning | End       | P     |
|-------------------|-----------|-----------|-------|
| Weight, kg        | 65.87±11.53 | 65.85±11.49 | 0.771 |
| BMI, kg/m²        | 24.42±3.6  | 24.39±3.49 | 0.681 |
| Woundsize, cm²    | 277.88±100 | ----      | ----  |

Student's t test for independent samples. Data presented as mean ± standard deviation. BMI = Body mass index, kg = kilograms; kg / m² = kilograms per square meter.

The mean weight before supplementation was 65.87 ± 11.53 kg and at the end 65.85 ± 11.49 kg, no significant differences were found; BMI 24.42 ± 3.6 kg/m² which is interpreted as a Normal body mass index according to the WHO and at the end 24.39 ± 3.49 kg/m²; no significant differences were found. The mean of the wounds size was 277.88 ± 100 cm², the final measurement was not obtained because some patients underwent a surgical procedure before taking the measurement.

| Diagnóstico de ingreso | N  | %     |
|------------------------|----|-------|
| Bloody area by fire projectile | 2  | 11.80 |
| Bloody area by car accident        | 7  | 41.20 |
| Bloody area by cold weapon          | 4  | 23.50 |
| Others                             | 4  | 23.50 |

Data is presented in frequencies and percentage respect to the total sample (n=17)

The admission diagnosis with more frequency was car accident (41.20%) followed by, cold weapon wound (23.50%) and others (23.50%) in which it is included: work accident, fall greater than two floors, everyday accident, with lower frequency by fire projectile (11.80%)
At the end of the supplementation the control group had a lymphocytes mean of 8.440 ± 3.35 units/field and the treatment group: 12.50 ± 7.69 units/field, without significant differences (p = 0.330) but with a medium effect size (d = 0.68); the macrophages in the control group of 5.44 ± 4.64 units/field and the treatment group 5.00 ± 2.44 units/field, without differences (p = 0.806). A granulocyte mean of 6.44 ± 6.78 units/field was observed in the control group and 11.25 ± 10.25 units/field at treatment group, without significant differences (p = 0.237) with a medium effect size (d = 0.55) and an increased at the end in the treatment group. A tendency to increase in the fibroblast count was observed in both groups at the end of the treatment with significant differences between the means (p = 0.015); with a large effect size (d = 1.14). Finally, in the new blood vessel formation count 3.50 ± 2.99 units/field were reported in the control group and 7.25 ± 3.10 units/field in the treatment group, with significant differences (p = 0.036), and a large effect size. (d = 1.23) (Graph 1).

Graph 1: Histogram of units/field ± standard deviation between groups after treatment

On a daily basis, a symptomatology questionnaire was applied to the patients in both groups, the frequencies at the end of the supplementation are shown in the following table:

| Symptomatology  | control Before n1(%) | After n1(%) | treatment Before n2(%) | After n2 (%) |
|-----------------|-----------------------|-------------|-------------------------|--------------|
| Stomachache     | 2 (22.2)              | 1 (11.1)    | 1 (12.5)                | 0 (0.00)     |
| Vomitting       | 2 (22.2)              | 1 (11.1)    | 1 (12.5)                | 0 (0.00)     |
| Nauseas         | 5 (55.5)              | 2 (22.2)    | 3 (37.5)                | 0 (0.00)     |
| General weakness| 6 (66.6)              | 2 (22.2)    | 6 (75.0)                | 1 (12.50)    |
| Headache        | 2 (22.2)              | 0 (0.0)     | 2 (25.0)                | 0 (0.00)     |
| Badmood         | 2 (22.2)              | 3 (33.3)    | 3 (37.5)                | 1 (12.50)    |
Edema
Diabetes
Constipation
Appetite loss

|         | Control | Treatment |
|---------|---------|-----------|
| Edema   | 5 (55.5)| 2 (22.2)  |
| Diabetes| 4 (44.4)| 2 (22.2)  |
| Constipation | 1 (11.1)| 0 (0.0) |
| Appetite loss | 4 (44.4)| 2 (22.2) |

Data presented in frequencies and percentages before and after supplementation referring to the number of patients who presented the symptomatology. n1 = 9 patients in the control group, n2 = 8 patients in the treatment group.

At the end of 15 days the control group showed higher frequencies in symptomatology compared to the treatment group. In first place, there is a decrease in the frequency of patients who showed general weakness in the treatment group from 75% to 12.50%, who reported an increase in the sensation of physical energy. There was a decrease in the frequency of patients who showed diarrhea from 37.5% to 0% which indicates better consistency in the evacuations. The feeling of nausea decreased in both groups, from 55.5% to 22.2% in the control group and from 37.5% to 0.0% in the treatment group. These symptoms were reported before the supplementation and patients themselves related nausea and vomiting to anesthesia side effects.

**Discussion:**

It is considered, that this is one of the few formal research studies that have been accomplished with: glutamine (14g/d) and hydroxymethylbutyrate (HMB 3g/d), since the literature review yielded little information about it and arginine has been added to the mixture in other studies. The biggest effect was observed in Fibroblasts and Angiogenesis, both reported significant differences between groups at the end of the supplementation, with a large effect size. In comparison with another study of similar characteristics where the histology of the wound was evaluated subjectively (inflammation, reepithelialization, granular tissue, collagen and angiogenesis) where no significant differences were found between the parameters attributed to the lack of standardization in the protein supplementation between groups (p > 0.05).

The tendency to increase found in the results agree with that described by Witte et al. about the difference in appearance time of the cells in the wound during the healing process, macrophages are predominant during inflammation taking its maximum peak between the 4th and 6th day after the wound, while the lymphocyte count increases to its maximum peak on the 6th day and a decrease is expected from day 10-14, this cells are predominant, along with the fibroblasts, during the proliferative phase with maximum peaks around day 8-13 rising to the maturation phase, decreasing the degradation of the damaged extracellular matrix and increasing the production of collagen III.

Biochemical parameters were measured in order to monitor the protein metabolism such as albumin, total proteins, blood urea nitrogen and creatinine, no significant differences were observed and levels were maintained within normal range which is why the results are not reported. Results differ from reported by Rathmacher where blood urea nitrogen increased in a HMB+arginina+glutamine supplemented group unlike the results in this study, mainly because the supplementation was different resulting as extra nitrogen consumed, so it is relevant to evaluate the importance or not of arginine in supplementation.

Regarding the symptomatology, it is worth mentioning that the patients who received the treatment reported improvement in: general well-being, increased appetite and better intestinal transit (referred to as a better consistency in the evacuations by those who presented diarrhea and a higher number of evacuations in those who presented constipation); which was not observed in those who received placebo.

It should be mentioned that the sample size could have limited the results of the study, despite this; the results demonstrate that the mixture of glutamine and HMB as daily supplementation can have a positive effect on the cells involved in the healing process. It is considered that the perspective of the study is to continue the research on the benefits of immunonutrition on wound healing in different pathologies, in addition the need to carry out a new study
including cluster differentiation in order to specifically identify the type of cells observed and designing and in which the long-term permanence of the effect can be evaluated.

Acknowledgments:
We kindly thank Evolution Nutraceutical Company S.A. of C.V. for the donation of amino acids without conflict of interest.

References:
1. Quain A, Khardori M. Nutrition in Wound Care Management: A comprehensive Overview. Wounds. 2015; 27(12):327-35.
2. Dryden S, Shoemaker W, Kim J. Wound Management and Nutrition for Optimal Wound Healing. Atlas Oral Maxillofacial SurgClin N Am. 2013; 21(1):37-47.
3. Montoya-Montoya N, Munera-García. Efecto de la intervención nutricional temprana en el resultado clínico de pacientes con riesgo nutricional. Nutr Hosp. 2014; 29(1) 427-36.
4. Stechmiller J. Understanding the Role of Nutrition and Wound Healing. Nutrition in Clinical Practice. Nutr Clin Pract. 2010; 25(1):61-8.
5. Vesga A, Canboa E. Riesgo de malnutrición asociado a baja ingesta alimentaria, estancia hospitalaria prolongada y reingreso en un hospital de alto nivel de complejidad en Colombia. Nutr Hosp. 2015; 32(3):1308-1314.
6. Rodríguez B, Laquaniiti N, Merkel M, Villagra A. Política Nutricional activa en la implementación del soporte nutricional hospitalario: resultados de un estudio observacional. Nutr Hosp. 2014; 30(2):447-452.
7. Harris C, Bates-Jensen B, Parslow N, Raizman R, Singh M. The Bates-Jensen Wound Assessment Tool (BWAT): Development of a Pictorial Guide for Training Nurses. Wound Care Canada. 2009 Julio; 7(2): 253-9.
8. Baker L, Gout B, Crowe T. Hospital Malnutrition; prevalence, identification and impact on patients and the healthcare system. Int J Environ Res Public Health 2011; (8): 514-527.
9. Lizaka S, Okuwa M, Sugama J, Sanada H. The impact of malnutrition and nutrition-related factors on the development and severity of pressure ulcers in older patients receiving home care. Clin Nutr 2010; (29):47-53.
10. Chow O, Barbul A. Immunonutrition: Role in Wound Healing and Tissue Regeneration. WHS. 2012; 3(1): 46–53.
11. Usctegui H. Inmunonutrición: Enfoque en el paciente quirúrgico. Rev Chil Circ 2010; 62 (1): 87-92.
12. Kurkalec K, Jezska J, Podgorski T. The effect of a 12-week beta-hydroxy-beta-methylbutirate (HMB) Supplementation on Highly-Trained Combat Sports Athletes: A randomized, double-blind, placebo-controlled crossover study. Nutrients, 2017; (9): 1-21.
13. Jones M, Rivera M, Puccinelli C, Wang M, Williams S, A B. Targeted Amino Acid Supplementation in Diabetic Foot Wounds: Pilot Data and a Review of the Literature. Surgical Infections. 2014; 15(6): 708-12.
14. Cruz-Jentoff A. Beta-hydroxy-beta-methyl butyrate (HMB): From experimental data to clinical evidence in sarcopenia. Curr Protein Pept Sci. 2017; (28): 668-672.
15. Wing A, Chow A, Wang A, Ong L, Zhang S, Young S. The use of a specialized amino acid mixture for pressure ulcers: A placebo-controlled trial. Journal of Wound Care. 2014; 23(5): 259-60, 262-4, 266-9.
16. Armstrong D, Hanft J, Driver V, Smith P, Lazaro J, Reyzelman A, et al. Effect of oral nutritional supplementation on wound healing in diabetic foot ulcers: a prospective randomized controlled trial. Diabet Med. 2014; 31.
17. Sipahi S, Gungor O, Gunduz M, Cilci M, Cahit M, Tamaa A. Te effect of oral supplementation with a combination of beta-hydroxy-beta-methylbutirate, arginine, and glutamine on wound healing: a retrospective analysis of diabetic haemodialysis patients. BMC Nephrol 2013; 14(8): 1-6.
18. Wandrag L, Brett S, Frost G, Hickson M. Impact of supplementation with amino acids or their metabolites on muscle wasting in patients with critical illness or other muscle wasting illness: a systematic review. J Hum Nutr Diet. 2015; 28(4):313-30.
19. Haldun R, Temel H, Osman B, Ersoy E, Yazgan A, Yildirim Z. The mixture of Arginine, Glutamine, and B-hydroxy-b-methyl Butyrate Enhances the Healing of Ischemic Wounds in Rats. J PEN J Parenter Enteral Nutr. 2017; 41(6):1045-1050.
20. Yavas C, Yavas G, Acar H, Toy H, Yuce D, Akyurek S, et al. Amelioration of radiation-induced acute inflammation and mucosal atrophy by beta-hydroxy-beta-methylbutyrate, L-glutamine, and L-arginine: results of an experimental study. Support Care Cancer 2013; (21):883–888
21. Wu H, Xia Y, Jiang J, Du, Guo X, Liu X, et al. Effect of beta-hydroxy-beta-methylbutyrate supplementation on muscle loss in older adults: A systematic review and meta-analysis. Arch Gerontol Geriatr. 2015; 61 (2):168-75.

22. Sipahi S, Gungor O, Gunduz M, Cici M, Cahit M, Tamer A. The effect of oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine on wound healing: a retrospective analysis of diabetic haemodialysis patients. BMC Nephrol. 2013; (14)8: 1-6.

23. May P, Barber A, D'Olimpio J, Hourihane A, Abumrad N. Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine. Am J Surg. 2002; (182): 471–479.

24. Clark R, Feleke G, Din M, Yasmine T, Singh G, Khan F, et al. Nutritional Treatment for Acquired Immunodeficiency Virus-Associated Wasting Using β-Hydroxy β-Methylbutyrate, Glutamine, and Arginine: A Randomized, Double-Blind, Placebo-Controlled Study. Eur J Clin Nutr. 2016; 70(2): 269–273.

25. Osman B, Riza H, Eren E, cols y. A Pilot experimental study on the effect of arginine, glutamine, and β-hydroxy-b-methylbutyrate on secondary wound healing JPEN J Parenter Enteral Nutr. 2017 Aug;41(6):1045-1050.

26. Ratchmater J, Nissen S, Panton L, Clark R, May P, Barber A, et al. Supplementation with a combination of beta-hydroxy-beta-methylbutyrate (HMB), arginine, and glutamine is safe and could improve hematological parameters. JPEN J Parenter Enteral Nutr. 2004; 28(2):65-75.

27. Witte M, Barbul A. General principles of wound healing. Surg Clin North Am. 1997; 77(3):509-28.

28. Achamrah N, De’chelotte P, Coe’ffier M. Glutamine and the regulation of intestinal permeability: from bench to bedside. Curr Opin Clin Nutr Metab Care. 2017; 20(1):86-91.

29. Bardhan P. Improving the ORS: Does Glutamine have a Role? J Health Popul Nutr. 2007; 25(3): 263–266.